INTRODUCTION
This is part one of a two-part state of the arthepatoblastoma. The companion, part two, article deals with PRE-Treatment EXTent of tumor (PRETEXT) radiographic staging, surgical guidelines and liver transplantation and also appears in this issue. Over the last 4 decades, overall survival in hepatoblastoma has increased from roughly 30% to over 80%, primarily because of advances in chemotherapy and in our ability to achieve complete surgical resection, even in the most advanced of tumors. Detailed herein are some of the key advances in histopathology, epidemiology, genetics, chemotherapy, and risk stratification that have helped drive the improved survival seen in hepatoblastoma.
HISTOPATHOLOGY AND EPIDEMIOLOGY OF HEPATOBLASTOMA
annual percentage increase in the incidence of hepatoblastoma during the last 30 years. Indeed, the incidence does seem to be slowly increasing, with a current rate of 1.2-1.5 cases/million population/ year. Because premature birth and very low birth weight have been found to be associated with the later appearance of hepatoblastoma, increase in these patient cohorts may be driving the increase in incidence [7 & ]. Oxygen therapy, medications such as furosemide, Total Parenteral Nutrition (TPN), radiation, plasticizers, and other toxins are postulated to perhaps play a role, but the exact mechanisms are not yet understood.
Hepatoblastoma is an embryonal tumor thought to originate from a hepatocyte precursor cell (hepatoblast) that often recapitulates the stages of liver development, displaying a combination of histological patterns [8] . Clinical trials have demonstrated that, in addition to staging, some histological types are also associated with prognosis [9] . One early review showed that 67% of hepatoblastomas were epithelial, with a combination of mixed embryonal and fetal patterns, and 21% displayed a mesenchymal component in addition to the common epithelial patterns. Most importantly, approximately 7% of the total were composed of a pure, well differentiated fetal (WDF) epithelial component, and 5% demonstrated primitive appearing or socalled small cell undifferentiated (SCU) tumor cells [10] . Since then, several studies have demonstrated a correlation between improved survival and WDF histology composed only of cells resembling fetal hepatocytes with minimal mitotic activity. In a recent Children's Oncology Group (COG) publication, Malogolowkin et al. [11] reported that, whenever complete tumor specimens can be resected and evaluated prior to chemotherapy, patients with WDF histology [formerly referred to as pure fetal histology (PFH)] and low mitotic activity may be treated exclusively with surgery, and no chemotherapy is necessary. Patients with WDF/PFH histology completely resected upfront and receiving no postoperative chemotherapy comprised 7% of the total number of patients (COG studies INT-0098 and P9645) and showed 100% event-free survival (EFS). This is in striking contrast to other international protocols, which historically have treated all children with liver tumors and elevated alphafetoprotein (AFP) with chemotherapy prior to surgical resection [12 && ]. It is important to remember, though, that most hepatoblastomas are extremely heterogeneous, often with closely intermixed histological components, and only rarely composed of a single histological type [13 && ]. A second histological subtype worth mentioning is the SCU. This may be part of an otherwise typical hepatoblastoma, representing a component intermixed with other histologies or present as the sole component in the so-called 'pure small cell' hepatoblastoma. This histologic pattern is sometimes associated with low serum AFP levels and poor response to chemotherapy. The first report regarding the negative association of SCU component was by Kasai and Watanabe, followed by Haas's Children's Cancer Group-Pediatric Oncology Group (CCG-POG, also referred to as COG legacy groups) report, in which none of the patients with small cell hepatoblastoma survived 24 months after the diagnosis [14, 15] . Trobaugh-Lotrario et al. [16] recently reviewed a large series of hepatoblastoma with small cell histology and confirmed 11 patients with SCU hepatoblastomas presenting with clinically normal or minimally increased serum AFP levels, none of whom survived. Interestingly, six of these tumors were INI1 nuclear negative by immunohistochemical staining and three of them demonstrated cytogenetic and molecular abnormalities similar to those seen in rhabdoid tumors, suggesting that some, but not all, of these tumors may represent INI1-negative neoplasms within the spectrum of primary rhabdoid tumors. However, the significance of small cell component when admixed with other epithelial types, and whether these small foci are sometimes INI1 expressing, is still under investigation. Participants in the Los Angeles 2011 International Pathology Pediatric Liver Symposium agreed upon a panel of immunohistochemical stains
KEY POINTS
New international pediatric hepatoblastoma consensus classification (Table 1) includes histological subtypes and categories, recognizing how challenging some tumors are to classify, particularly after chemotherapy.
CHIC risk factor analysis (Table 3) shows refined prognostic estimates in smaller subgroups than previously possible by interrogating a collaborative dataset that includes comprehensive data on 1605 children treated by the four major hepatoblastoma study groups between 1989 and 2008. SIOPEL 4 shows an impressive improvement in survival for metastatic patients using a novel schema that incorporated weekly dose-dense cisplatin chemotherapy (Table 6 ).
COG, SIOPEL/GPOH, and JPLT are now collaborating to develop a cooperative international hepatoblastoma trial, fostering our ability to compare the historic differences between the chemotherapeutic and surgical approaches of different study groups and enhance biologic study in this rare tumor.
including INI1, which should be closely correlated with the morphology in order to further characterize this pattern and its prognostic significance. In addition, the group recommended that all INI1-negative tumors should be submitted for molecular testing, and patients and family members referred to a genetic counselor to possibly be screened for germline mutations whenever appropriate [13 && ]. The rarity of hepatoblastoma, combined with the rarity of upfront resection, has resulted in a paucity of complete annotated prechemotherapy specimens, compromising biology studies. Therefore, several international conferences have been sponsored to foster international collaboration and clinical trials. As a result of these meetings, recommendations were outlined for submission, sampling, and evaluation of pediatric liver tumor samples, including minimum diagnostic specimen requirements and evaluation of the uninvolved liver, as well as the necessity of providing minimal clinical information to the reviewer, which should always include age, AFP level at the time of diagnosis, underlying liver disease, and correlation with imaging [13 && ]. There was also consensus between the pathologists regarding the importance of obtaining prechemotherapy specimens for the initial diagnoses and tumor classification. Finally, the group also highlighted the importance of tissue banking for biological studies [13 && ]. The newly proposed pathology consensus of pediatric hepatoblastoma classification (Table 1 ) [13 && ] includes all prognostically relevant histological types (WDF and SCU), as well as the new categories ('pleomorphic epithelial' and 'malignant hepatocellular neoplasm'), recognizing how challenging some tumors are to classify, particularly after chemotherapy. Reviewers also highlighted the importance of appropriately sampling and following specimen submission recommendations, as well as the imperative need to characterize the biology of hepatoblastoma, pediatric hepatocellular carcinoma, and other hepatocellular neoplasms, and to identify biological markers that could be used for tumor classification, clinical stratification, and to develop new novel therapeutic strategies. 
PREDICTING PROGNOSIS: GENETICS
Several prognostic markers and constitutional genetic syndromes such as Trisomy 18/Edward's syndrome, BWS, and FAP have been reported in association with hepatoblastoma [17] . There have been at least seven published cases of hepatoblastoma in children with trisomy 18/Edward's syndrome. BWS predisposes to a number of embryonal tumors and the overall percentage of children with BWS who develop tumors is 7.5-13.5%, with the most frequent tumors being Wilms' tumor and hepatoblastoma. Regarding FAP, it appears that there may be genotype-phenotype links between specific mutations to the APC gene, which is mutated in FAP. In families with FAP and hepatoblastoma, referral to a genetic counselor is recommended.
The most frequent genetic aberrations (70-90%) in hepatoblastoma occur in genes involved in the Wnt signaling pathway [18, 19] . A majority of hepatoblastoma have Wnt signal abnormalities. Recently, telomerase activation and genetic expression profiles were identified as prognostic factors [20, 21] . Among 212 hepatoblastoma enrolled in Japanese Study Group for Pediatric Liver Tumors (JPLT)-2 between 2000 and 2010, large deletion of CTNNB1 was detected in 107 cases and mutation of CTNNB1 exon 3 was detected in 56 cases. Approximately 80% had abnormalities of these factors, including APC and Axin genes. Immunohistochemistry revealed b-catenin was accumulated in the tumor cells with Wnt signal aberrations. Not all, but a majority, of the samples showed elevated expression of Wnt signal target genes such as cyclin D1, survivin, and MYC.
Telomerase, the activated enzyme related to cell immortality, is a reverse transcriptase for the elongation of telomeres, is regulated by the expression of TERT (human telomerase reverse transcriptase), and is a catalytic component of human telomerase [22, 23] . Wnt signal activation usually occurs in aggressive tumors, TERT expression plays a major role in Wnt signal activation, and MYC (an activated Wnt signal target gene) enhances TERT expression. As a result, activation of TERT and MYC signaling appears to play a role in the more aggressive phenotypes of hepatoblastoma [24, 25] . Additionally, recent microarray analysis by Cairo and colleagues revealed a 16-gene signature that discriminated invasive and metastatic hepatoblastoma and predicted prognosis. These 16 genes were the highly proliferating subclass typified by upregulated MYC signaling [26] . These findings support the MYC activation theory by Wnt signaling activation in aggressive hepatoblastoma, again suggesting that a TERT and MYC vicious cycle may exist in aggressive tumors.
PREDICTING PROGNOSIS: RISK STRATIFICATION AND CLINICAL PROGNOSTIC FACTORS
The four major study groups -International childhood liver tumors strategy group (SIOPEL), COG, German Society for Pediatric Oncology (GPOH), and JPLT -have historically had disparate risk classification categories, making it difficult to compare the outcomes across the oceans. Fortunately, all groups have increasingly used the PRETEXT grouping system for risk stratification, as discussed in Part Two of this review. Over the last 10 years, individual study groups have attempted to define the relative importance of a variety of suspected prognostic factors present at diagnosis and in response to therapy [9, 11, 27, 28, 29 && ,30] ( Table 2 ). In SIOPEL, good prognostic factors have included low PRETEXT at diagnosis (PRETEXT I, II, and III tumors) [28] . In COG, good prognosis has been shown for Stage I tumors resected at diagnosis and tumors with pure fetal histology [9, 11] . Poor prognostic factors identified individually in these trials include PRETEXT IV, metastatic disease, AFP less than 100, and SCU histology [9, 27] . Other variables such as tumor rupture prior to diagnosis, tumor multifocality, macrovascular tumor invasion, extrahepatic tumor extension, age at diagnosis, very high (>1.2 million) or borderline low (100-1000) AFP have been suggested as poor prognostic factors, but the relative importance of their prognostic significance has been difficult to define [29 && ]. Factors in response to treatment that had been hypothesized as poor prognostic factors include poor response or progressive disease on chemotherapy, gross positive surgical margins, surgically unresectable tumor, and tumor relapse.
Efforts to define clinical prognosis in hepatoblastoma have historically been challenging because of the low numbers of patients, even in multicenter trials. To address this challenge, the Children's Hepatic tumor International Collaboration (CHIC) initiative was formed to combine the results of multicenter trials by SIOPEL, COG, JPLT, and GPOH over the last 20 years and thereby gain enhanced statistical power with increased numbers. In cooperation with the data management group Consorzio Interuniversitario (CINECA), CHIC created a dataset that includes comprehensive data on all children treated in 11 separate trials by the four major hepatoblastoma study groups between 1989 and 2008, a total of 1605 patients [31] . Univariate analysis was used to identify statistically significant prognostic variables, which were then included in a backwards elimination multivariate analysis to identify those constellations of variables most predictive of outcome [30] . Factors significant by univariate analysis at diagnosis were PRETEXT, AFP less than 100, AFP 100-1000, metastatic disease, age group, macrovascular involvement vena cava/hepatic veins (þV), macrovascular involvement portal veins (þP), contiguous extrahepatic tumor (E), multifocal disease, and spontaneous rupture at diagnosis. Multivariate analysis of these factors led to the selection of a risk backbone based upon PRETEXT I/II, PRETEXT III, PRETEXT IV, AFP less than 100, and metastatic disease. Within each of these backbone groups, the presence or absence of the remaining risk factors was further stratified by multivariate estimates of EFS (Table 3 ) [30] . This statistical effort is ongoing and has not yet been rigorously validated. Upon maturation of outcome data from the current COG trial, AHEP0731, the CHIC group hopes to combine the data of AHEP0731 and SIOPEL 4 to form a validation set for the CHIC risk groups. Moreover, validation and refinement of these risk groups is one of the primary objectives in the planning for an upcoming international collaborative hepatoblastoma therapeutic trial.
HEPATOBLASTOMA MULTICENTER TRIALS
Treatment of hepatoblastoma in children represents a true success story of pediatric oncology in the last 25 years. From prechemotherapy survival rates in the 1970s of 30%, the use of adjuvant and neoadjuvant chemotherapy brought the patients' survival to 70-80%. This progress was possible not only because of the introduction of new drugs (i.e. cisplatin and doxorubicin), but also because of the new surgical approaches (i.e. hepatic exclusion, Pringle, ultrasonic dissection, liver transplantation) and, perhaps most importantly, because of multicenter cooperative efforts of the major international study groups (Table 4 ) [27, [32] [33] [34] [35] [36] [37] [38] [39] .
One fundamental controversy between various study groups has been the issue of primary hepatic resection, with SIOPEL recommending preoperative chemotherapy in every case, in every patient, and in every tumor. The other groups have traditionally carved out some lower-risk groups amenable to upfront resection. The initial American approach (INT-0098,P9645) put the upfront surgical decision in the hands of the individual surgeon and recommended an attempt at upfront resection in everyone. The old COG Evan's stages I, II, and III were based upon the surgeon's success or failure to resect the tumor at diagnosis. In those who were not 'resectable', biopsy only was performed, followed by chemotherapy, delayed surgery, and postoperative chemotherapy. In those who were resectable, a primary partial hepatectomy was followed by postoperative chemotherapy [39] . The current COG trial, AHEP-0731, has moved away from putting surgical decisions arbitrarily in the hands of an individual surgeon. This study's surgical guidelines recommend upfront resection only for PRETEXT I and II tumors, when the diagnostic imaging shows clear radiographic margins on the contralateral portal vein, the middle hepatic vein, and the retrohepatic inferior vena cava [40] .
The evolution of chemotherapeutic approaches is well illustrated by following the progression of results shown in Table 4 . Contemporary chemotherapy protocols from the four major study groups AFP, alphafetoprotein; CARBO, carboplatin; CCG, Children's Cancer Group; CDDP, cisplatin; CITA, Cisplatin/Pirarubicin; COG, Children's Oncology Group; C5V, cisplatin þ 5-fluorouracil (5FU) þ vincristine; DOXO, doxorubicin; EFS, event-free survival; GPOH, German Society for Pediatric Oncology; HR, high risk; IFOS, ifosfamide; JPLT, Japanese Study Group for Pediatric Liver Tumors; Mets, metastatic; OS, overall survival; PLADO, cisplatin þ doxorubicin; POG, Pediatric Oncology Group; PRETEXT, pre-treatment extent of tumor; SIOPEL, international childhood liver tumors strategy group; SR, standard risk; SUPERPLADO, cisplatinþ doxorubicin þ carboplatin; THPA, tetrahydropyranyl adriamycin; VP, etoposide. Data from [27, [32] [33] [34] [35] [36] [37] [38] . a Study closed early because of inferior results in CDDP/CARBO arm.
,42]. SIOPEL 4 shows an impressive improvement in survival for metastatic patients using a novel schema that incorporated weekly dose-dense cisplatin chemotherapy. The results are startling and strike one as almost too good to be true, with 98% (60 of 61 evaluable patients) experiencing a partial response and only 1 of 20 who achieved a pulmonary complete response having relapse [43] . As a single-arm trial, SIOPEL 4 was not randomized; rather, outcomes were compared with historical controls, and therefore further study will be needed before it can be adopted as the standard of care. A total of 97% of patients had grade 3-4 hematologic toxicity. This is consistent with some adult studies that have used a similar approach and may be considered acceptable. However, fever and neutropenia occurred in 71% of patients and four patients had toxic deaths (two from infection, one from surgical bleeding, and one with tumor bleeding). The number of patients with significant hearing loss was greater than 50%. As ototoxicity is difficult to measure, notoriously underreported, and can progress over time, the question remains as to what hearing function these very young patients will have in the long run. The SIOPEL 4 results suggest that this regimen should be compared in a randomized trial, further evaluating the toxicities of this design, and, in fact, planning is underway to study this regimen in the high-risk arm of a new international trial being planned as a joint effort between COG, SIOPEL/GPOH, and JPLT. Additionally, as exciting as these results are, it emphasizes the urgent need for new agents to address that subset of tumors that remain unresponsive. Novel strategies have been investigated by JPLT and COG. In JPLT-2, the use of high-dose chemotherapy with autologous stem cell/bone marrow transplant rescue was used in the highest-risk patients, but was not found to improve survival [39] . COG AHEP-0731, in collaboration with JPLT, is studying patients using vincristine-irinotecan and vincristine-irinotecan-temsirolimus in metastatic patients in a novel upfront window design prior to beginning standard COG C5V-D chemotherapy (cisplatin, 5FU, vincristine, and doxorubicin) [44 & ].
CHEMOTHERAPY, PROGRESSIVE DISEASE AND TUMOR RELAPSE: NEW DEVELOPMENTS IN CHEMOTHERAPY
Few conventional chemotherapy agents have demonstrated activity in progressive or relapse hepatoblastoma [45] . Doxorubicin, carboplatin, etoposide, and ifosfamide have been used as part of rescue strategies and have been incorporated in upfront therapy for high-risk patients as well [46] [47] [48] .
Approximately one-third of the patients whose disease progressed or recurred after initial treatment without anthracyclines could be successfully rescued with a doxorubicin-containing regimen and surgery [46] . Irinotecan has been used experimentally as a maintenance therapy in a handful of patients suspected of being at high risk for relapse [47] . A SIOPEL phase 2 study investigated irinotecan in 28 patients with relapse and progressive disease on conventional chemotherapy. Of the 23 evaluable patients, 6 had a partial response, 11 had stable disease, and 6 had progressive disease. Irinotecan appeared to have significant antitumor activity in a small but real subset of these patients [49] . Highdose chemotherapy with stem cell rescue has been used in the setting of progressive or relapsed hepatoblastoma. However, as the available data is based on case reports or small series with potential for selection bias, the role and efficacy of this approach are still unknown [38, [50] [51] [52] . Hepatic intra-arterial chemoembolization has been shown to be efficacious in shrinking these tumors and allowing complete surgical resection after initial systemic chemotherapy [53, 54] . Surgical resection of relapse nodules in the lungs can be curative, but has a high failure rate [55] . Agents like irinotecan and oxaliplatin have been tested in small numbers of patients with relapse [48, 56, 57] . Whereas irinotecan has shown to have some activity, no objective response was seen for hepatoblastoma in a phase II study of oxaliplatin [57] . Newer targeted agents that 'selectively' interfere with the pathway targets involved in tumor growth, progression, and vascular development, such as insulin-like growth factor (IGF), phosphatidylinositol 3-kinase (PI3K), mammalian target of rapamycin (mTOR), and vascular endothelial growth factor (VEGF), are currently under development. Gene-directed treatment approaches and immunotherapy have high potential as future treatment options. Both therapy options have displayed promising results in preclinical models so far, but are clearly only in the infancy of their scientific evaluation [58] [59] [60] [61] [62] [63] [64] [65] .
CONCLUSION
Further understanding of the histopathologic subtypes and molecular mechanisms responsible for the development and progression of these tumors is essential to prioritize the most promising agents for clinical evaluation. International cooperation is necessary for the continuous improvement in the outcomes of these patients and the advancement in the knowledge of the genetics, epidemiology, and biology of these tumors. With the foundation provided by the CHIC, work is now well underway in the formation of a new cooperative international hepatoblastoma trial, fostering our ability to compare the historic differences between the chemotherapeutic and surgical approaches of different study groups and define the true state of the art.
